

Application No.: 10/559,694

2

Docket No.: 64609(70301)

AMENDMENTS TO THE CLAIMSRECEIVED  
CENTRAL FAX CENTER

This listing of claims will replace all prior versions, and listing, of claims in the application.

DEC 26 2007

**Listing of Claims:**

1 (Currently amended). A method for the prophylaxis and/or therapy of portal hypertension, the method comprising administering a dose of 0.0001 to 1000 mg/kg body weight use-of an inhibitor of phosphodiesterase type 5 (PDE 5), or of a pharmaceutical composition containing a PDE 5-inhibitor, for the prophylaxis and/or therapy of portal hypertension.

2 (Currently amended). A method for the prophylaxis and/or therapy against one or more of the following diseases or complications: bleeding complications of the portal hypertension, hepato-renal syndrome, hepato-pulmonary syndrome, hepatic encephalopathy, spontaneous bacterial peritonitis and ascites, the method comprising administering a portal blood flow increasing amount use-of an inhibitor of phosphodiesterase type 5 (PDE 5), or of a pharmaceutical composition containing a PDE 5-inhibitor, for the prophylaxis and/or therapy against one or more of the following diseases or complications: bleeding complications of the portal hypertension, hepato-renal syndrome, hepato-pulmonary syndrome, hepatic encephalopathy, spontaneous bacterial peritonitis and ascites.

3 (Currently amended). A method for the prophylaxis and/or therapy against illnesses or disease conditions, which can be controlled by a decrease of the portal vein pressure and/or by an increase of the portal vein flow, or which can be prevented thereby, the method comprising administering, respectively, a portal vein pressure decreasing amount and/or a portal vein flow increasing amount use-of a PDE 5-inhibitor, or of a pharmaceutical composition containing a PDE 5-inhibitor, for the prophylaxis and/or therapy against illnesses or disease conditions, which can be controlled by a decrease of the portal vein pressure and/or by an increase of the portal vein flow, or which can be prevented thereby.

B032\_643614.1

4 (Currently amended). The method use according to any one of claims 1 to 3, the method further comprising prophylaxis and/or therapy against bleedings from oesophagus varices and/or fundus varices.

5 (Currently amended). A method for influencing the metabolism of a substance, wherein the influencing involves an increase of the portal vein flow and, thus, an increase of a blood flow through the liver, the method comprising administering a portal blood flow increasing amount use of a PDE 5-inhibitor, or of a pharmaceutical composition containing a PDE 5-inhibitor, for influencing the metabolism of a substance, wherein the influencing involves an increase of the portal vein flow and thus an increase of a blood flow through the liver.

6 (Currently amended). The method use according to claim 5, wherein the influencing involves an enhanced metabolic decomposition of an exogenously added substance in the liver.

7 (Currently amended). The method use according to claim 5 or 6, wherein the substance is an exogenously added substance, which is incorporated concurrently with, after, or particularly prior to the administering use of the PDE 5-inhibitor or the pharmaceutical composition containing a PDE 5-inhibitor, and/or wherein the exogenous substance is selected from the group consisting of medicaments, drugs or toxic substances such as ethyl alcohol.

8 (Currently amended). The method use according to any one of claims 1 to 3 or 5 to 7, wherein the PDE 5-inhibitor is selected from the group consisting of Sildenafil, Tadalafil and Vardenafil.

9 (Currently amended). The method use according to claim 8, wherein Vardenafil is selected as the PDE 5-inhibitor.

10 (Currently amended). The method use according to any one of claims 1 to 3, 5 to 7 or 9 the preceding claims for the prophylaxis and/or therapy in, wherein the PDE 5-inhibitor is administered to a human humans.

11 (Currently amended). The method use according to any one of claims 1 to 3, 5 to 7 or 9 the preceding claims, wherein the PDE 5-inhibitor or the pharmaceutical composition containing a PDE 5-inhibitor is administered orally.

12 (Currently amended). The use according to claim 1110, wherein the single dose of the PDE 5-inhibitor is administered orally as a single dose in the oral administration is an amount of 0.01 to 10, particularly 0.1 to 1.5 mg PDE 5-inhibitor per kg body weight.

13 (Currently amended). The method use according to any one of claims 1 to 3, 5 to 7, 9 or 1112, the method comprising administering the PDE 5-inhibitor in combination with a-an additional substance, which is selected from the group of  $\beta$ -blockers, Vasopressin and analogs thereof as well as Somatostatin and analogs thereof.

14 (Withdrawn). Combination-medication for the prophylaxis and/or therapy against portal hypertension and/or against disease conditions or risks which are associated with the portal hypertension,  
wherein the combination medication comprises the following combination, in a common or in separate application form(s):

- a PDE 5-inhibitor, and
- another drug against portal hypertension.

15 (Withdrawn). Combination-medication according to claim 14, wherein the other drug against portal hypertension is selected from conventional drugs against portal hypertension, particularly from a group consisting of  $\beta$ -blockers, Vasopressin and analogs thereof as well as Somatostatin and analogs thereof.

Application No.: 10/559,694

5

Docket No.: 64609(70301)

16 (Withdrawn) Combination-medication according to claim 14, wherein the PDE 5-inhibitor is selected from the group consisting of Sildenafil, Tadalafil and Vardenafil.

B052\_643614.1